Literature DB >> 20628400

Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay.

Brian T Hawkins1, Robert R Rigor, David S Miller.   

Abstract

Blood-brain barrier (BBB) P-glycoprotein activity is rapidly reduced by vascular endothelial growth factor (VEGF) acting via Src and by tumor necrosis factor-alpha acting via protein kinase C (PKC)beta1. To probe underlying mechanism(s), we developed an in vivo, immunoblot-based proteinase K (PK) protection assay to assess the changes in the P-glycoprotein content of the BBB's luminal membrane. Infusion of PK into the brain vasculature selectively cleaved luminal membrane P-glycoprotein, leaving intracellular proteins intact. Intracerebroventricular injection of VEGF partially protected P-glycoprotein from proteolytic cleavage, consistent with transporter internalization. Activation of PKCbeta1 did not protect P-glycoprotein. Thus, VEGF and PKCbeta1 reduce P-glycoprotein activity by distinct mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20628400      PMCID: PMC2949254          DOI: 10.1038/jcbfm.2010.117

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  13 in total

1.  Xenobiotic transport across isolated brain microvessels studied by confocal microscopy.

Authors:  D S Miller; S N Nobmann; H Gutmann; M Toeroek; J Drewe; G Fricker
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors:  Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-12       Impact factor: 4.553

3.  Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.

Authors:  William R Friedenberg; Montserrat Rue; Emily A Blood; William S Dalton; Chaim Shustik; Richard A Larson; Pieter Sonneveld; Philip R Greipp
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

Review 4.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

5.  Expression of P-glycoprotein in human cerebral cortex microvessels.

Authors:  Daniela Virgintino; David Robertson; Mariella Errede; Vincenzo Benagiano; Francesco Girolamo; Eugenio Maiorano; Luisa Roncali; Mirella Bertossi
Journal:  J Histochem Cytochem       Date:  2002-12       Impact factor: 2.479

6.  Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain.

Authors:  Robert R Rigor; Brian T Hawkins; David S Miller
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-03       Impact factor: 6.200

7.  Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein.

Authors:  H R Goodfellow; A Sardini; S Ruetz; R Callaghan; P Gros; P A McNaughton; C F Higgins
Journal:  J Biol Chem       Date:  1996-06-07       Impact factor: 5.157

8.  Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation.

Authors:  L M Roberts; D S Black; C Raman; K Woodford; M Zhou; J E Haggerty; A T Yan; S E Cwirla; K K Grindstaff
Journal:  Neuroscience       Date:  2008-06-13       Impact factor: 3.590

9.  Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells.

Authors:  U A Germann; T C Chambers; S V Ambudkar; T Licht; C O Cardarelli; I Pastan; M M Gottesman
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

10.  Proteolytic Cleavage of the Linker Region of the Human P-glycoprotein Modulates Its ATPase Function.

Authors:  Shanthy L Nuti; U Subrahmanyeswara Rao
Journal:  J Biol Chem       Date:  2002-06-07       Impact factor: 5.157

View more
  21 in total

1.  Identification of P-glycoprotein co-fractionating proteins and specific binding partners in rat brain microvessels.

Authors:  Margaret E Tome; Charles P Schaefer; Leigh M Jacobs; Yifeng Zhang; Joseph M Herndon; Fabian O Matty; Thomas P Davis
Journal:  J Neurochem       Date:  2015-04-21       Impact factor: 5.372

Review 2.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery.

Authors:  Thomas P Davis; Lucy Sanchez-Covarubias; Margaret E Tome
Journal:  Adv Pharmacol       Date:  2014-08-23

Review 4.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

5.  Sphingolipid signaling reduces basal P-glycoprotein activity in renal proximal tubule.

Authors:  David S Miller
Journal:  J Pharmacol Exp Ther       Date:  2014-01-02       Impact factor: 4.030

6.  Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.

Authors:  Tara A Cartwright; Christopher R Campos; Ronald E Cannon; David S Miller
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-21       Impact factor: 6.200

7.  Distinct roles of ezrin, radixin and moesin in maintaining the plasma membrane localizations and functions of human blood-brain barrier transporters.

Authors:  Yutaro Hoshi; Yasuo Uchida; Takashi Kuroda; Masanori Tachikawa; Pierre-Olivier Couraud; Takashi Suzuki; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2019-08-14       Impact factor: 6.200

Review 8.  Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Authors:  Sagar Agarwal; Anika M S Hartz; William F Elmquist; Björn Bauer
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

9.  P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia.

Authors:  Gwen McCaffrey; William D Staatz; Lucy Sanchez-Covarrubias; Jessica D Finch; Kristen Demarco; Mei-Li Laracuente; Patrick T Ronaldson; Thomas P Davis
Journal:  J Neurochem       Date:  2012-07-10       Impact factor: 5.372

10.  PPAR-α, a lipid-sensing transcription factor, regulates blood-brain barrier efflux transporter expression.

Authors:  Vijay R More; Christopher R Campos; Rebecca A Evans; Keith D Oliver; Gary Ny Chan; David S Miller; Ronald E Cannon
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.